IND-enabling ADME studies to predict drug-drug interaction.
Testing for mRNA and enzyme activity for a comprehensive portfolio of inducible enzymes, including CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, UGTs and transporters
In vitro inhibition testing for a range of drug metabolizing enzymes, including CYPs (reversible and TDI), UGTs, Oxidases (e.g., AO, MAO), and Esterases (e.g., CES, ChE)
Comprehensive Phase I/II (CYP, UGT, AO/XO, FMO, CES, SULT) enzyme identification using Gentest Supersomes®, human liver fractions and human hepatocytes, including enzyme kinetics (Km, CLint) and fm determination (selective chemical inhibition, RAF/ISEF scaling)
Customized ADME analyses on unusual drug metabolizing enzymes, screening, custom IND enabling study requirements
Advanced LC-MS/MS bioanalysis supporting small molecules, lipids, peptides, and oligonucleotides (ASO, siRNA) across in vitro and in vivo matrices
Optimized siRNA, GalNAc-siRNA, oligo or mRNA delivery into hepatocytes, screening and functional read outs
Customized characterization of available hepatocyte lots, generation of custom pools from a selection of available lots
